We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Nixes CES Reclassification; Benefits Don’t Trump Lack of Data
Panel Nixes CES Reclassification; Benefits Don’t Trump Lack of Data
February 17, 2012
Despite few safety risks, a sharply divided FDA advisory panel voted not to reclassify cranial electrotherapy stimulation (CES) devices from Class III to Class II because of a lack of data to support the products’ efficacy.